Jan 26, 2022 / 09:30PM GMT
Operator
Greetings, and welcome to the Cue Biopharma update call. (Operator Instructions) As a reminder, this conference is being recorded.
I would now like to turn the conference over to Dan Passeri, Cue Biopharma's Chief Executive Officer. Thank you. You may begin.
Daniel R. Passeri - Cue Biopharma, Inc. - CEO & Director
Okay. Thank you, and good afternoon, everyone. We appreciate your time and interest in our update call regarding recent data and observations from our ongoing clinical trials of CUE-101, which is our first drug candidate representative of the IL-2-based CUE-100 series.
Joining me on today's call is Dr. Anish Suri, our President and Chief Scientific Officer; Dr. Ken Pienta, our acting Chief Medical Officer; and Dr. Matteo Levisetti, our Senior Vice President of Clinical Development.
So this conference is being recorded and will be available on our website for the next 30 days. As a reminder, and as shown here on Slide #2, this presentation and overview may contain some forward-looking statements. And any forward-looking
Cue Biopharma Inc To Host Business Update And Ongoing CUE-101 Clinical Trials Call Transcript
Jan 27, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers